Metabolomics in Cancer Research

Abstract

Metabolomics has emerged as a transformative tool in cancer research, offering insights into the altered metabolic states that drive tumor initiation, progression, and therapeutic resistance. Cancer cells exhibit profound metabolic reprogramming, including enhanced glycolysis (Warburg effect), altered lipid metabolism, and dysregulated amino acid pathways, which support their rapid proliferation and survival. By analyzing the comprehensive profile of metabolites in cells, tissues, and biofluids, metabolomics enables the identification of unique metabolic signatures associated with different cancer types and stages. Advanced analytical techniques such as mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy facilitate high-resolution metabolic profiling, leading to the discovery of novel biomarkers for early diagnosis, prognosis, and therapeutic monitoring. Furthermore, metabolomics provides critical insights into the tumor microenvironment, highlighting interactions between cancer cells and surrounding stromal or immune cells. This approach also aids in elucidating mechanisms of drug resistance, unveiling potential metabolic vulnerabilities that can be targeted for therapy. The integration of metabolomics with other omics technologies, such as genomics and proteomics, offers a systems-level understanding of cancer biology, paving the way for precision oncology. As the field continues to evolve, metabolomics holds immense promise for advancing personalized cancer treatment and improving patient outcomes.

DOI - https://doi.org/10.65525/SVUP.9788198800428.2025.26-33